Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Curr Oncol Rep. 2012 Oct;14(5):433–440. doi: 10.1007/s11912-012-0255-7

Table 2.

Phase III Trials of Idiotype Vaccines in Follicular Lymphoma

Author Sponsor Idiotype Used Induction Therapy Response Required End Point Results
Levy et al Genitope Recombinant CVP × 8 CR or PR PFS NS
Freedman et al Favrille Recombinant Rituximab × 4 CR, PR, or stable disease TTP NS
Schuster et al NCI/Biovest Hybridoma PACE to best response, R-CHOP CR or CRu DFS Significant